BACKGROUND: Little is known about real-world outcomes for new interferon-free treatment for hepatitis C virus (HCV) among underserved and diverse communities. OBJECTIVE: To identify predictors of treatment prescription and evaluate outcomes as measured by sustained virologic response (SVR) with HCV RNA testing three months after therapy completion. DESIGN: Retrospective cohort at a safety-net health care system. PARTICIPANTS: Patients with (1) at least one clinical visit between December 6, 2013, and December 31st 2014; and (2) at least three months follow-up. KEY RESULTS: Predominantly non-White cohort (61%). Of 1,284 HCV-infected patients 121 prescribed sofosbuvir-based therapy. Severe liver fibrosis (OR 1.66, 95% CI 1.05, 2.64) independently associated with treatment prescription. In those with evaluable HCV RNA, SVR was 99%. CONCLUSION: Cure rates similar to clinical trial data can be achieved in diverse underserved communities.
BACKGROUND: Little is known about real-world outcomes for new interferon-free treatment for hepatitis C virus (HCV) among underserved and diverse communities. OBJECTIVE: To identify predictors of treatment prescription and evaluate outcomes as measured by sustained virologic response (SVR) with HCV RNA testing three months after therapy completion. DESIGN: Retrospective cohort at a safety-net health care system. PARTICIPANTS: Patients with (1) at least one clinical visit between December 6, 2013, and December 31st 2014; and (2) at least three months follow-up. KEY RESULTS: Predominantly non-White cohort (61%). Of 1,284 HCV-infected patients 121 prescribed sofosbuvir-based therapy. Severe liver fibrosis (OR 1.66, 95% CI 1.05, 2.64) independently associated with treatment prescription. In those with evaluable HCV RNA, SVR was 99%. CONCLUSION: Cure rates similar to clinical trial data can be achieved in diverse underserved communities.
Authors: Yngve Falck-Ytter; Hemangi Kale; Kevin D Mullen; Steedman A Sarbah; Lucian Sorescu; Arthur J McCullough Journal: Ann Intern Med Date: 2002-02-19 Impact factor: 25.391
Authors: Soumitri Barua; Robert Greenwald; Jason Grebely; Gregory J Dore; Tracy Swan; Lynn E Taylor Journal: Ann Intern Med Date: 2015-08-04 Impact factor: 25.391
Authors: Shruti H Mehta; Becky L Genberg; Jacquie Astemborski; Ravi Kavasery; Gregory D Kirk; David Vlahov; Steffanie A Strathdee; David L Thomas Journal: J Community Health Date: 2008-06
Authors: Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane Journal: N Engl J Med Date: 2013-04-23 Impact factor: 91.245
Authors: Kris V Kowdley; Stuart C Gordon; K Rajender Reddy; Lorenzo Rossaro; David E Bernstein; Eric Lawitz; Mitchell L Shiffman; Eugene Schiff; Reem Ghalib; Michael Ryan; Vinod Rustgi; Mario Chojkier; Robert Herring; Adrian M Di Bisceglie; Paul J Pockros; G Mani Subramanian; Di An; Evguenia Svarovskaia; Robert H Hyland; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; David Pound; Michael W Fried Journal: N Engl J Med Date: 2014-04-10 Impact factor: 91.245
Authors: Zobair M Younossi; Haesuk Park; Staurt C Gordon; John R Ferguson; Aijaz Ahmed; Douglas Dieterich; Sammy Saab Journal: Am J Manag Care Date: 2016-05 Impact factor: 2.229
Authors: Sabrina A Assoumou; Wei Huang; C Robert Horsburgh; Mari-Lynn Drainoni; Benjamin P Linas Journal: Open Forum Infect Dis Date: 2014-05-14 Impact factor: 4.423
Authors: Sabrina A Assoumou; Jianing Wang; Shayla Nolen; Golnaz Eftekhari Yazdi; Kenneth H Mayer; Jon Puro; Joshua A Salomon; Benjamin P Linas Journal: J Gen Intern Med Date: 2020-03-04 Impact factor: 5.128
Authors: Rachel A Stewart; Brooke R MacDonald; Tzu-Chun Chu; Jonathan D Moore; Esther O Fasanmi; Rohit P Ojha Journal: Dig Dis Sci Date: 2018-07-16 Impact factor: 3.199